Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Group is working with Solvotrin Therapeutics (Solvotrin), based in Cork, Ireland. Solvotrin is a drug development company focused on optimising established therapies, vitamins and minerals using innovative science to deliver value for significant unmet clinical needs. Read More ...
Posted on 27 Apr 2017

Sage Represents Mateon Therapeutics - Leadershp in Novel Vascular Targeted Therapy

Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology indications. The company has two VDAs in clinical development, CA4P and OXi4503, the lead one of which is being studied in a phase 2/3 clinical trial in platinum resistant ovarian cancer. Read More ...
Posted on 28 Dec 2016